P&G Buys Thorne for $3.8 Billion, Betting on DTC Data Over Shelf Space
Procter & Gamble is paying $3.8 billion for supplement brand Thorne, CEO Shailesh Jejurikar confirmed on CNBC's Squawk on the Street on August 4. The all-cash deal, expected to close in the fourth quarter of 2026, moves Thorne from private equity ownership under L Catterton into one of the largest consumer goods portfolios in the world.
For a brand founded in 1984 that spent most of its life selling almost exclusively through healthcare practitioners, the acquisition marks a genuine turning point, and the terms of the deal reveal exactly what P&G thinks it's actually buying.
What P&G Is Really Paying For
Thorne's revenue surpassed $500 million in 2025. Most of that revenue comes from shoppers under 40, and the brand has seen real, sustained growth in its direct-to-consumer channel specifically.
That DTC relationship is the actual asset here, not the product catalog. Thorne built its brand around clinical credibility, NSF Certified for Sport status, and a personalization model anchored by Taia, an AI wellness advisor that helps individual customers navigate a large product line. The brand has accumulated roughly seven million direct consumer relationships through that model, a dataset and customer base P&G could not easily replicate by launching a competing product internally.
P&G Health Care CEO Paul Gama framed the deal around that positioning directly: “Consumer interest in self-care, prevention, wellness, and personalized health continues to grow, and Thorne strengthens our position in premium wellness with a trusted, science-backed brand that complements our existing portfolio.”
Why P&G Needs This Deal Right Now
The acquisition lands at an uncomfortable moment for P&G's own numbers. In the fiscal fourth quarter reported July 29, net income fell to $3.04 billion from $3.62 billion a year earlier, even as net sales rose 2% to $21.2 billion. Organic sales, which strip out currency effects, acquisitions, and divestitures, were flat for the quarter. The health care segment posted the steepest volume decline of any division P&G reports.
P&G is also mid-restructuring. A two-year program announced in June 2025 will eliminate roughly 7,000 jobs, about 15% of the company's non-manufacturing workforce, and is projected to cost between $1 billion and $1.6 billion in pre-tax charges, partly to offset $600 million in tariff-related cost pressure. Jejurikar has described fiscal 2026 as a year of foundation-building, with deliberate focus shifting toward premium brands where consumers have shown real willingness to pay more.
Buying a fast-growing, premium-positioned brand with a young, direct customer base fits that stated strategy precisely, at a moment when P&G's own organic growth engine has stalled.
Where the Real Tension in This Deal Sits
P&G's core competitive advantage has never been direct customer relationships. It's shelf presence, scale distribution, and getting a product in front of as many shoppers as possible at the lowest possible cost. Thorne's value proposition runs in the opposite direction: a practitioner-endorsed, personalized, DTC-first brand built on a direct relationship between the company and the individual customer.
Putting a Thorne SKU on a shelf next to Metamucil and Align Probiotic at Walmart is a commercially sensible move for P&G's existing playbook. Whether that placement is consistent with the clinical, personalized positioning that built Thorne's customer base in the first place is a separate question, one the acquisition doesn't answer on its own.
Thorne CEO Colin Watts addressed that tension directly in his own statement: “We believe P&G is the right partner to help us expand our impact while staying true to the values and standards that have always defined Thorne.” Whether that holds once Thorne sits inside a company built around mass retail distribution rather than practitioner trust and DTC personalization is the real test of this deal over the next few years, not the purchase price.
A Bigger Pattern in Big CPG's Wellness Playbook
Thorne is not an isolated purchase. Unilever acquired gummy supplement brand Grüns earlier this year, reportedly after also bidding on Thorne and losing to P&G's offer. The pattern across major consumer goods companies is consistent: rather than building competing DTC wellness brands from scratch internally, they're acquiring the ones that already won.
That's a meaningful signal if you run a DTC supplement, wellness, or health brand with real traction and a defined, loyal customer base. The strategic value acquirers like P&G are paying for isn't your current product catalog. It's your direct customer relationships, your data, and your credibility with an audience under 40 that traditional CPG brands have struggled to reach organically. Building that kind of asset, rather than optimizing purely for near-term revenue, is what makes a DTC brand acquisition-worthy to a buyer like P&G, Unilever, or any other major strategic acquirer circling this category right now.
